Tricyclic spiro compound
US11192876B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2019 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Dec 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.